Saudi Arabia Pain Management Market Research Report Forecast to 2030 Market Overview The growth of the Saudi Arabia pain management market is attributed to the rising incidence of chronic diseases and the development of novel pain management products and techniques, which are driving the growth of the Saudi Arabia pain management market. However, the side effects associated with treatments are attributed to retarding market growth. Nonetheless, it is anticipated that increasing investment in healthcare within the country will create lucrative opportunities in the coming years. Pain management refers to a medical specialty that involves the assessment, diagnosis, and treatment of different types of pain. The goal of pain management is to alleviate pain, improve the patient's quality of life, and promote physical and mental well-being. Pain can be acute, which is typically associated with a sudden injury or illness, or chronic, which is characterized by pain that persists for several months or longer. The Saudi Arabia-pain management market is emerging due to the increasing prevalence of chronic diseases such as cancer and diabetes, along with the development of novel pain management devices and techniques. Additionally, the increasing investment in healthcare within the country will provide growth opportunities for the market in the future. However, side effects associated with treatments might hamper the market's growth in the forecast period. Market Segmentation Based on product, the Saudi Arabia pain management market has been segmented into devices and drugs. The devices were segmented into neurostimulation, electrical stimulators, analgesic infusion pumps, and others. Based on application, the Saudi Arabia pain management market has been segmented into neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, post-operative pain, and others. Based on end users, the Saudi Arabia Pain management market has been segmented into hospitals & clinics, ambulatory surgical centers, and others. Major Players Pfizer, Inc. (US), AbbVie Inc. (US), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), GlaxoSmithKline Plc (UK), Sanofi (France), Baxter International Inc. (US), Abbott (US), Medtronic (Ireland), Boston Scientific Corporation (US).

1 EXECUTIVE SUMMARY 10 1.1 OVERVIEW 10 2 MARKET INTRODUCTION 11 2.1 DEFINITION 11 2.2 SCOPE OF THE STUDY 11 2.3 RESEARCH OBJECTIVE 11 2.4 MARKET STRUCTURE 11 2.5 ASSUMPTIONS & LIMITATIONS 12 3 RESEARCH METHODOLOGY 13 3.1 DATA MINING 13 3.2 SECONDARY RESEARCH 14 3.3 PRIMARY RESEARCH 15 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 16 3.5 FORECASTING TECHNIQUES 17 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 18 3.6.1 BOTTOM-UP APPROACH 19 3.6.2 TOP-DOWN APPROACH 19 3.7 DATA TRIANGULATION 19 3.8 VALIDATION 20 4 MARKET DYNAMICS 21 4.1 OVERVIEW 21 4.2 DRIVERS 22 4.2.1 RISING INCIDENCE OF CHRONIC DISEASES 22 4.2.2 DEVELOPMENT OF NOVEL PAIN MANAGEMENT DEVICES AND TECHNIQUES 22 4.3 RESTRAINTS 24 4.3.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS 24 4.4 OPPORTUNITY 25 4.4.1 INCREASING INVESTMENT IN HEALTHCARE 25 5 MARKET FACTOR ANALYSIS 26 5.1 VALUE CHAIN ANALYSIS 26 5.1.1 R&D 27 5.1.2 MANUFACTURING 27 5.1.3 DISTRIBUTION & SALES 27 5.1.4 POST-SALES MONITORING 27 5.2 PORTER'S FIVE FORCES MODEL 28 5.2.1 THREAT OF NEW ENTRANTS 28 5.2.2 BARGAINING POWER OF SUPPLIERS 29 5.2.3 THREAT OF SUBSTITUTES 29 5.2.4 BARGAINING POWER OF BUYERS 29 5.2.5 INTENSITY OF RIVALRY 29 5.3 IMPACT OF COVID-19 ON THE SAUDI ARABIA PAIN MANAGEMENT MARKET 30 5.3.1 IMPACT ON SUPPLY CHAIN 30 5.3.2 IMPACT ON KEY PLAYERS 30 5.3.3 IMPACT ON DEMAND 30 5.4 MARKET INSIGHTS: DEMOGRAPHIC ANALYSIS SAUDI ARABIA 31 5.4.1 POPULATION 31 5.4.2 AGE GROUP DEMOGRAPHICS 31 5.4.3 GENDER DISTRIBUTION 32 5.4.4 GDP 32 6 SAUDI ARABIA PAIN MANAGEMENT MARKET, BY PRODUCT 33 6.1 OVERVIEW 33 6.2 DEVICES 35 6.2.1 NEUROSTIMULATION 35 6.3 DRUGS 36 6.3.1 NON-NARCOTIC ANALGESICS 36 7 SAUDI ARABIA PAIN MANAGEMENT MARKET, BY APPLICATION 37 7.1 OVERVIEW 37 8 SAUDI ARABIA PAIN MANAGEMENT MARKET, BY END USER 40 8.1 OVERVIEW 40 9 COMPETITIVE LANDSCAPE 43 9.1 OVERVIEW 43 9.2 COMPETITIVE BENCHMARKING 44 9.3 FINANCIAL MATRIX 45 9.3.1 SALES (USD MILLION), 2021 45 9.3.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021 45 10 COMPANY PROFILES 46 10.1 ABBOTT 46 10.1.1 COMPANY OVERVIEW 46 10.1.2 FINANCIAL OVERVIEW 47 10.1.3 PRODUCTS OFFERED 47 10.1.4 KEY DEVELOPMENTS 48 10.1.5 SWOT ANALYSIS 49 10.1.6 KEY STRATEGIES 49 10.2 ABBVIE, INC 50 10.2.1 COMPANY OVERVIEW 50 10.2.2 FINANCIAL OVERVIEW 51 10.2.3 PRODUCTS OFFERED 51 10.2.4 KEY DEVELOPMENTS 52 10.2.5 KEY STRATEGIES 52 10.3 MEDTRONIC 53 10.3.1 COMPANY OVERVIEWS 53 10.3.2 FINANCIAL OVERVIEW 54 10.3.3 PRODUCTS OFFERED 54 10.3.4 KEY DEVELOPMENTS 55 10.3.5 SWOT ANALYSIS 55 10.3.6 KEY STRATEGIES 55 10.4 BOSTON SCIENTIFIC CORPORATION 56 10.4.1 COMPANY OVERVIEW 56 10.4.2 FINANCIAL OVERVIEW 57 10.4.3 PRODUCTS OFFERED 57 10.4.4 KEY DEVELOPMENTS 58 10.4.5 SWOT ANALYSIS 58 10.4.6 KEY STRATEGIES 58 10.5 NOVARTIS AG 59 10.5.1 COMPANY OVERVIEW 59 10.5.2 FINANCIAL OVERVIEW 60 10.5.3 PRODUCTS OFFERED 61 10.5.4 KEY DEVELOPMENTS 61 10.5.5 KEY STRATEGIES 61 10.6 PFIZER, INC 62 10.6.1 COMPANY OVERVIEW 62 10.6.2 FINANCIAL OVERVIEW 63 10.6.3 PRODUCTS OFFERED 63 10.6.4 KEY DEVELOPMENTS 64 10.6.5 SWOT ANALYSIS 64 10.6.6 KEY STRATEGIES 64 10.7 GLAXOSMITHKLINE PLC 65 10.7.1 COMPANY OVERVIEW 65 10.7.2 FINANCIAL OVERVIEW 66 10.7.3 PRODUCTS OFFERED 67 10.7.4 KEY DEVELOPMENTS 67 10.7.5 SWOT ANALYSIS 68 10.7.6 KEY STRATEGIES 68 10.8 SANOFI 69 10.8.1 COMPANY OVERVIEW 69 10.8.2 FINANCIAL OVERVIEW 69 10.8.3 PRODUCTS OFFERED 70 10.8.4 KEY DEVELOPMENTS 70 10.8.5 KEY STRATEGIES 70 10.9 BAXTER INTERNATIONAL INC 71 10.9.1 COMPANY OVERVIEW 71 10.9.2 FINANCIAL OVERVIEW 72 10.9.3 PRODUCTS OFFERED 72 10.9.4 KEY DEVELOPMENTS 72 10.9.5 KEY STRATEGIES 73 10.10 FRESENIUS KABI AG 74 10.10.1 COMPANY OVERVIEW 74 10.10.2 PRODUCTS OFFERED 75 10.10.3 KEY DEVELOPMENTS 75 10.10.4 KEY STRATEGIES 75 11 APPENDIX 76 11.1 REFERENCES 76 11.2 RELATED REPORTS 77